TRGNF Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -- compared to Transgene SA's net margin of -253.13%. Transgene SA's return on equity of -182.92% beat Cellectis SA's return on equity of -65.19%.

Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Cellectis SA has higher upside potential than Transgene SA, analysts believe Cellectis SA is more attractive than Transgene SA.

Transgene SA has a beta of 45.447, which suggesting that the stock is 4444.7% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.

Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Transgene SA quarterly revenues are $105.2K, which are smaller than Cellectis SA quarterly revenues of $10.4M. Transgene SA's net income of -- is lower than Cellectis SA's net income of -$26.3M. Notably, Transgene SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 865.90x versus 4.85x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat DBV Technologies SA's return on equity of -217.87%.

Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that DBV Technologies SA has higher upside potential than Transgene SA, analysts believe DBV Technologies SA is more attractive than Transgene SA.

Transgene SA has a beta of 45.447, which suggesting that the stock is 4444.7% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Transgene SA quarterly revenues are $105.2K, which are larger than DBV Technologies SA quarterly revenues of --. Transgene SA's net income of -- is lower than DBV Technologies SA's net income of -$44.8M. Notably, Transgene SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 865.90x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat Innate Pharma SA's return on equity of -72.79%.

Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $6.00 which suggests that it could grow by 337.96%. Given that Innate Pharma SA has higher upside potential than Transgene SA, analysts believe Innate Pharma SA is more attractive than Transgene SA.

Transgene SA has a beta of 45.447, which suggesting that the stock is 4444.7% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.338%.

Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Transgene SA quarterly revenues are $105.2K, which are larger than Innate Pharma SA quarterly revenues of --. Transgene SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Transgene SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 865.90x versus 37.39x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Nicox SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat Nicox SA's return on equity of -43.13%.

Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Transgene SA has higher upside potential than Nicox SA, analysts believe Transgene SA is more attractive than Nicox SA.

Transgene SA has a beta of 45.447, which suggesting that the stock is 4444.7% more volatile than S&P 500. In comparison Nicox SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 107.966%.

Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.

Transgene SA quarterly revenues are $105.2K, which are larger than Nicox SA quarterly revenues of --. Transgene SA's net income of -- is lower than Nicox SA's net income of --. Notably, Transgene SA's price-to-earnings ratio is -- while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 865.90x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.